Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

I think there’s common ground here,” one Republican congressman said Wednesday during a House Budget Committee hearing.

Novo shares have surged more than 20% amid oral Wegovy’s fast start. Elsewhere, Terns opened up room for a potential ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...